Acetyl Gastric Inhibitory Peptide (human) (TFA)  (Synonyms: Human N-acetyl GIP TFA)

Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity^[1][2][3].

Acetyl Gastric Inhibitory Peptide (human) TFA induces cyclic adenosine 3'5' monophosphate (cAMP) production with an EC₅₀ value of 1.9 nM in Chinese hamster lung fibroblast cells transfected with the human GIP receptor^[1].
Acetyl Gastric Inhibitory Peptide (human) TFA (10^-13-10^-8 nM) shows potent effect at stimulating insulin release compared to the native GIP in BRIN-BD11 cells^[1].
Acetyl Gastric Inhibitory Peptide (human) TFA improves glucose intolerance, type 2 diabetes, beta-cell glucose insensitivity, insulin resistance and reduced insulin secretion^[2].
Acetyl Gastric Inhibitory Peptide (human) TFA has metabolic stability and hypoglycemic and insulin modulating activities of two fatty acid derivatized N-terminally acetylated GIP analogs were evaluated in in vitro and in vivo^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Acetyl Gastric Inhibitory Peptide (human) TFA (25 nmol/kg; i.p.; single dose) shows resistance to plasma dipeptidylpeptidase IV degradation, resulting in enhanced biological activity and improved antidiabetic potential in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

5139.62

C₂₂₈H₃₄₀N₆₀O₆₇S.C₂HF₃O₂

Solid

White to off-white

Ac-Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln

Ac-YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• [1]. O'Harte FP, et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia. 2002 Sep;45(9):1281-91.  [Content Brief]

  [2]. Gault Victor A, et al. GIP peptide analogues for treatment of diabetes, insulin resistance and obesity: World Intellectual Property Organization, WO2005082928[P]. 2005-12-01.

  [3]. O'Harte, et al. Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function: World Intellectual Property Organization, WO2007028632[P].2007-03-15.